The Boehringer Ingelheim Veterinary Development Team (from left to right): David Cahill MVB LLB MRCVS, Charlotte Jennings BVetMed MRCVS and Janet Winter BVMS CertVR CertCIM MRCVS
Boehringer Ingelheim Launches New Business Development Initiative
Boehringer Ingelheim Animal Health has launched a new business development initiative delivered by its Veterinary Development team, which will support practices in implementing evidence-based veterinary medicine and help grow their businesses.
Boehringer’s Veterinary Development Partners are all experienced small animal clinicians who are equipped to work with veterinary clinics and implement independent clinical audits on their behalf. Clinical audit provides a methodology to apply evidence-based veterinary medicine and is widely considered within human healthcare to be the most effective way to improve and optimise patient care. Clinical audit is a ‘no-blame’ process which helps engage all clinic staff in a culture of continuous improvement and education.
“At Boehringer Ingelheim we believe in helping our customers do the right thing. Clinical audit provides a well-established framework to help us do exactly that,” comments Rebecca Maher, Veterinary Affairs Lead at Boehringer Ingelheim. “Importantly though, our Veterinary Development Partners don’t just identify gaps through the audit process, but they also partner with our customers to help them identify and implement plans and solutions which enable them to close those gaps, delivering the best clinical outcomes for patients, promoting high staff morale and pet owner satisfaction, and of course helping our customers’ businesses thrive,”
To find out more about the services which Boehringer Ingelheim’s Veterinary Development team can offer your clinic, contact your local Boehringer Territory Manager.
Ends
Photo shows: The Boehringer Ingelheim Veterinary Development Team (from left to right): David Cahill MVB LLB MRCVS, Charlotte Jennings BVetMed MRCVS and Janet Winter BVMS CertVR CertCIM MRCVS.
For further press information, please contact:
Jessica Henman at MG Communications on 01488 683862 or email [email protected]
An educational service from Boehringer Ingelheim Animal Health UK Ltd (“BI”). Further information available from BI, RG12 8YS, UK. ©2019. All rights reserved. Date of preparation: Jun 2019. AHD12524. Use Medicines Responsibly.
More from Boehringer Ingelheim
- Boehringer Ingelheim receives FDA approval for SENVELGO® (velagliflozin oral solution): the first oral liquid medication for diabetes in cats
- Boehringer Ingelheim Animal Health launches new ProZinc webinar and toolkit
- NexGard Spectra ‘Yum and Done’ competition winner announced
- Boehringer Ingelheim launches Parassess - a “first-of-its-kind”, online, personalised dog parasite risk checker
- ABCD & Boehringer Ingelheim invite applications for the 2022 Young Scientist Award